Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • MJFF Research Grant, 2012
    Establishing LRRK2 Signaling Pathways

    Objective/Rationale:             
    Inherited mutations that cause Parkinson’s disease have been studied with earnest since their discovery beginning in the 1990’s.  These genetic alterations point us...

  • MJFF Research Grant, 2012
    Evaluation of PD-linked Transcripts in PPMI

    Objective/Rationale:             
    Confirm associations between the expression of three susceptibility genes and Parkinson’s in peripheral blood of individuals with early-stage, untreated disease, and...

  • MJFF Research Grant, 2012
    In Vivo Characterization of Helper-dependent Adenoviral Vectors Expressing Human LRRK2

    Objective/Rationale:             
    Mutations in the LRRK2 gene are a common cause of familial Parkinson’s disease. Familial LRRK2 mutations induce neuronal toxicity in vitro. Reliable pre-clinical...

  • Neurotrophic Factors Challenge, 2012
    Novel Cell-based Strategy for GDNF Delivery in Parkinson's Disease

    Objective/Rationale:             
    Glial cell line-derived neurotrophic factor (GDNF) is the most potent nerve cell growth molecule capable of protecting the dopamine neurons that are affected in...

  • LRRK2 in the Immune System, 2012
    Investigation of Neuroinflammation in LRRK2 Mutation Carriers Using Positron Emission Tomography

    Objective/Rationale:             
    There is evidence that LRRK2 mutation may alter the immune response in such as way as to potentiate neuroinflammatory responses to external triggers, with a...

  • Rapid Response Innovation Awards, 2012
    Targeting of 5-HT1A and 5-HT2A Receptors Against Levodopa-induced Dyskinesia

    Objective/Rationale:              
    Levodopa continues to be the gold-standard therapy for patients with Parkinson’s disease (PD). Unfortunately, effective long-term treatment is beset by abnormal...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.